Grants and Contributions:
Title:
SG-001 – Preliminary pharmacokinetic study of siRNA therapeutic
Agreement Number:
1034414
Agreement Value:
$18,990.00
Agreement Date:
Aug 20, 2025 - Feb 9, 2026
Description:
The project will support a pilot study for the lead asset - an siRNA for treatment of a bleeding disorder.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6T 1Z3
Reference Number:
172-2025-2026-Q2-1034414
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
713788008
Recipient Type:
For-profit organization
Recipient's Legal Name:
SERAGENE THERAPEUTICS INC.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710